What is the ICD‑10 code for temporal arteritis (giant cell arteritis)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

ICD-10 Code for Temporal Arteritis

The ICD-10 code for temporal arteritis (giant cell arteritis) is M31.6.

Understanding the Terminology

Temporal arteritis and giant cell arteritis (GCA) are synonymous terms referring to the same condition—a systemic vasculitis affecting large and medium-sized vessels, particularly the cranial arteries derived from the carotid artery 1. The condition is also documented in medical literature and classification systems under both names interchangeably 2, 3, 4.

Clinical Context for Proper Coding

When using this ICD-10 code, it's important to understand that:

  • Age requirement: GCA virtually never occurs in adults younger than 50 years of age 4, which is now an absolute requirement in the 2022 ACR/EULAR classification criteria 5

  • Disease manifestations: The code M31.6 encompasses both:

    • Cranial GCA (classic temporal arteritis with headache, scalp tenderness, jaw claudication)
    • Large vessel GCA (aortic and great vessel involvement) 1

Common Documentation Pitfalls

When coding for temporal arteritis, ensure proper documentation includes:

  • Confirmation method (temporal artery biopsy showing histopathological features of temporal arteritis, or imaging findings such as the "halo sign" on ultrasound) 1
  • Elevated inflammatory markers (ESR ≥50 mm/hour or CRP ≥10 mg/liter are present in >95% of cases at diagnosis) 1
  • Clinical manifestations that support the diagnosis

The code M31.6 should be used regardless of whether the diagnosis was confirmed by biopsy or imaging, as both are accepted diagnostic modalities 1.

References

Research

Giant cell arteritis and mortality.

The journals of gerontology. Series A, Biological sciences and medical sciences, 2009

Research

Giant cell arteritis: epidemiology, diagnosis, and management.

Current rheumatology reports, 2010

Research

Giant cell arteritis.

Postgraduate medicine, 2023

Related Questions

Which specialist is responsible for managing temporal arteritis?
In a patient over 50 with intermittent jaw pain that improves with a night mouthguard and a sensation of fluid dripping into the mouth, does this additional information change the recommended work‑up for giant‑cell arteritis and other possible oral or neuropathic causes?
What are the diagnostic criteria for giant cell arteritis in patients aged ≥50 years presenting with new‑onset headache, scalp tenderness, jaw claudication, visual disturbances, or abnormal temporal artery findings?
What are the key clinical features and bedside tests to differentiate giant cell arteritis, herpes zoster without a rash (zoster sine materia), and trigeminal neuralgia?
In patients older than 50 years, particularly women, what cranial ischemic manifestations occur in giant cell arteritis and what is the recommended immediate treatment?
What is the minimum platelet count required for safe endoscopic retrograde cholangiopancreatography (ERCP) and for high‑risk procedures such as sphincterotomy?
I have shoulder pain with limited range of motion; what conservative measures should I try and when should I seek further evaluation?
What is the appropriate starting dose of Strattera (atomoxetine) for children, adolescents, and adults?
What are the indications, dosing, application instructions, and contraindications for Estrogel (estradiol) compared to Divagel (testosterone)?
How can a prior right shoulder dislocation lead to mild glenohumeral arthritis and an undersurface acromial osteophyte 30 years later?
What is a safe dose of fish oil (eicosapentaenoic acid + docosahexaenoic acid) for a patient with chronic kidney disease stage 3A?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.